Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review

On November 10, 2026, the FDA approved Pimjetmi (pimicotinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity.¹ The once-daily oral kinase inhibitor had already received fast track and breakthrough therapy designations. It was reviewed under Project Orbis, the FDA Oncology Center of Excellence framework for concurrent review of oncology drugs with international partners.

The decision gives clinicians a second targeted oral option for patients whose tumors cannot be safely removed.¹ In February 2025 the FDA also approved vimseltinib (Romvimza) for the same indication, based on the phase 3 MOTION trial.²

What Did the MANEUVER Trial Show?

Efficacy was evaluated in MANEUVER (NCT05804045), a double-blind, randomized (2:1), placebo-controlled, international trial.¹ Eligible patients had symptomatic TGCT with at least 1 measurable lesion of 2 cm or larger.

At Week 25, overall response rate assessed by blinded independent central review was 56% (95% CI, 42, 68) with pimicotinib compared with 3.2% (95% CI, 0.1, 17) with placebo.¹ Median duration of response was not reached. Among responders, 32 (91%) maintained a response for at least 6 months and 27 (77%) for at least 12 months. The pimicotinib arm also showed statistically significant improvements across prespecified patient-reported and functional end points. These included active range of motion of the affected joint measured by goniometry, worst pain on the brief pain inventory worst pain numeric rating scale, and the patient-reported outcomes measurement information system physical function T-score.

The most common adverse reactions (> 20%) were pruritus, rash, face edema, periorbital edema, fatigue, nausea, headache, and peripheral edema.¹ The most common laboratory abnormalities (> 30%) were increases in creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, lipase, cholesterol, amylase, and alanine aminotransferase. Prescribing information includes warnings and precautions for hepatotoxicity, embryo-fetal toxicity, and increased serum creatinine without affecting renal function. The recommended dosage is 50 mg orally once daily, with or without food.

Why Does the Review Pathway Matter?

The FDA reviewed the application alongside several international regulators, and the EMA took part as an official observer.¹ Those applications may still be in submission or under review. The applicant also used the Assessment Aid, a voluntary submission meant to make FDA’s assessment more efficient.

This kind of review keeps showing up in oncology. GSK’s recent Jemperli filing was also accepted under Project Orbis, a further sign that coordinated multimarket review is becoming standard for oncology submissions.³ That means development and regulatory affairs teams have to plan filings and manufacturing readiness for all regions at once instead of one market at a time. Project Orbis reviews also compress global launch timelines, which pushes manufacturers to coordinate batch release and manage labeling that differs by region.⁴

Pimicotinib was already moving through other regulators.⁵ In June 2025, China’s Center for Drug Evaluation accepted Merck KGaA’s marketing application for the drug under priority review. With several regulators now reviewing the same oral small molecule in parallel, supply readiness, label harmonization, and postapproval change management become immediate operational priorities.

References

1. FDA. FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor. November 10, 2026. Accessed November 11, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-pimicotinib-symptomatic-tenosynovial-giant-cell-tumor
2. Ono Pharmaceutical. US FDA Grants Full approval of Deciphera’s Romvimza (vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT). News release. Feb. 14, 2025. Accessed November 11, 2026
3. GSK. Jemperli (dostarlimab) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer. News release. August 24, 2026. Accessed November 11, 2026. https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-accepted-for-priority-review-by-the-us-fda/
4. FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. FDA. News release. July 10, 2026. Accessed November 11, 2026.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin
5. Merck KGaA. China’s Center for Drug Evaluation accepts Merck KGaA, darmstadt, Germany’s application for marketing authorization of pimicotinib for treatment of tenosynovial giant cell tumor. News release. June 10, 2025. Accessed November 11, 2026.https://www.emdgroup.com/en/news/pimicotinib-china-nda-accept-10-05-2025.html